{"id":"fec-chemotherapy","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"5-10","effect":"Cardiotoxicity (epirubicin-related)"},{"rate":"50-70","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FEC combines fluorouracil (a thymidylate synthase inhibitor), epirubicin (a topoisomerase II inhibitor and DNA intercalator), and cyclophosphamide (an alkylating agent). Together, these agents attack cancer cells through multiple mechanisms: fluorouracil disrupts nucleotide synthesis, epirubicin intercalates into DNA and prevents replication, and cyclophosphamide cross-links DNA strands. The combination is designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:28.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and neoadjuvant treatment)"},{"name":"Early-stage and locally advanced breast cancer"}]},"trialDetails":[{"nctId":"NCT00911911","phase":"NA","title":"Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-02-22","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT00433420","phase":"PHASE3","title":"Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2003-04","conditions":"Breast Cancer","enrollment":2000},{"nctId":"NCT01996267","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2013-12","conditions":"Breast Cancer, HER2 Positive","enrollment":437},{"nctId":"NCT01822314","phase":"PHASE3","title":"Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2013-04","conditions":"Breast Cancer","enrollment":632},{"nctId":"NCT02620280","phase":"PHASE3","title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2016-04","conditions":"Invasive Ductal Breast Carcinoma","enrollment":278},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT00433589","phase":"PHASE3","title":"Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-02","conditions":"Breast Cancer","enrollment":6600},{"nctId":"NCT00087178","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-05","conditions":"Breast Cancer","enrollment":2722},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT02400567","phase":"PHASE2","title":"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":"Neoadjuvant Operable Breast Cancer","enrollment":125},{"nctId":"NCT02742051","phase":"PHASE2","title":"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-06","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT00943462","phase":"","title":"Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2009-06","conditions":"Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme","enrollment":""},{"nctId":"NCT01216111","phase":"PHASE3","title":"Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Triple Negative Breast Cancer","enrollment":647},{"nctId":"NCT04031703","phase":"PHASE3","title":"Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Breast Cancer","enrollment":647},{"nctId":"NCT01855828","phase":"PHASE2","title":"Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":"Her2-Positive Breast Cancer","enrollment":50},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT01867229","phase":"","title":"Breast Cancer and Chemo-amennorhea","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2011-10","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT03888677","phase":"PHASE3","title":"Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer","status":"COMPLETED","sponsor":"Henrik Lindman","startDate":"2001-02","conditions":"Breast Cancer","enrollment":1535},{"nctId":"NCT00513292","phase":"PHASE3","title":"Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07","conditions":"HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer","enrollment":280},{"nctId":"NCT03688958","phase":"PHASE2","title":"Iodine Supplementation on Breast Cancer","status":"UNKNOWN","sponsor":"Universidad Nacional Autonoma de Mexico","startDate":"2005-03-15","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00772824","phase":"PHASE4","title":"Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2007-12","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT03349177","phase":"PHASE2, PHASE3","title":"Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-11-27","conditions":"Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy","enrollment":200},{"nctId":"NCT02001506","phase":"PHASE3","title":"Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2012-11","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT01642771","phase":"PHASE3","title":"Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"China Breast Cancer Clinical Study Group","startDate":"2012-06","conditions":"Breast Cancer","enrollment":636},{"nctId":"NCT02365805","phase":"PHASE2","title":"Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-04","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225},{"nctId":"NCT00524303","phase":"PHASE2","title":"Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Neoplasms, Breast","enrollment":100},{"nctId":"NCT00499603","phase":"PHASE2","title":"Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07","conditions":"Breast Cancer","enrollment":62},{"nctId":"NCT01985841","phase":"PHASE2","title":"Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2011-10","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT02450058","phase":"PHASE3","title":"Adjuvant FEC Versus EP in Breast Cancer (MIG5)","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"1996-11","conditions":"Breast Cancer, Chemotherapy, Adjuvant","enrollment":1055},{"nctId":"NCT01563211","phase":"","title":"Predictive Model of Therapy Outcomes in Breast Cancer Patients","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-02","conditions":"Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.","enrollment":70},{"nctId":"NCT00593697","phase":"PHASE3","title":"The Synergism Or Long Duration (SOLD) Study","status":"COMPLETED","sponsor":"Finnish Breast Cancer Group","startDate":"2008-01","conditions":"Breast Neoplasms","enrollment":2168},{"nctId":"NCT00615602","phase":"PHASE3","title":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-10","conditions":"Breast Cancer","enrollment":489},{"nctId":"NCT00751868","phase":"PHASE2","title":"FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2008-09","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT00053911","phase":"PHASE3","title":"Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2002-11","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00256360","phase":"PHASE2","title":"Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2005-09","conditions":"Breast Cancer","enrollment":117},{"nctId":"NCT01740271","phase":"PHASE2","title":"A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients","status":"UNKNOWN","sponsor":"AHS Cancer Control Alberta","startDate":"2012-12","conditions":"Breast Neoplasms","enrollment":48},{"nctId":"NCT00425516","phase":"PHASE2","title":"Breast Cancer Treated by Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2007-01","conditions":"Individualized Chemotherapy","enrollment":264},{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754},{"nctId":"NCT01985724","phase":"PHASE3","title":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2007-10","conditions":"Breast Cancer","enrollment":650},{"nctId":"NCT00933517","phase":"PHASE2","title":"Assessment of the Efficacy of the Neoadjuvant Combination: \"Chemotherapy-Targeted Therapy\" in Breast Cancer.","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2009-09","conditions":"Pathological Response Rate","enrollment":62},{"nctId":"NCT00017095","phase":"PHASE3","title":"Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-03","conditions":"Breast Cancer","enrollment":1856},{"nctId":"NCT00054587","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2001-06","conditions":"Breast Cancer","enrollment":3010},{"nctId":"NCT00055679","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage I Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-08","conditions":"Breast Cancer","enrollment":1512},{"nctId":"NCT01537536","phase":"PHASE2","title":"Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2011-11","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT00047099","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2001-08","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT01159236","phase":"NA","title":"Molecular Triaging of Newly Diagnosed Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00038402","phase":"PHASE3","title":"Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-04","conditions":"Breast Cancer","enrollment":74},{"nctId":"NCT00670878","phase":"PHASE3","title":"Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-06","conditions":"Breast Cancer","enrollment":799},{"nctId":"NCT01180335","phase":"PHASE3","title":"Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-01","conditions":"Breast Cancer","enrollment":303},{"nctId":"NCT00336791","phase":"PHASE3","title":"Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":"Breast Cancer","enrollment":273},{"nctId":"NCT00544505","phase":"NA","title":"Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2007-09","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT00110695","phase":"PHASE2","title":"Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2005-04","conditions":"Breast Neoplasms","enrollment":66},{"nctId":"NCT00033683","phase":"PHASE2","title":"Combination Chemotherapy in Treating Women With Resected Breast Cancer","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2001-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00431080","phase":"PHASE3","title":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-08","conditions":"Breast Cancer","enrollment":478}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FEC Chemotherapy","genericName":"FEC Chemotherapy","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Breast cancer (adjuvant and neoadjuvant treatment), Early-stage and locally advanced breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}